Paraskevis

Greece
|
2022-2022
  • Elderly
  • Fragile population
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Cuadrado-Payán

Spain
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Huygens

The Netherlands
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Del Borgo

Italy
|
2022-2022
  • Adults
  • Elderly
  • Fragile population
  • Paediatric
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Piñana

Spain
|
2021-2023
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir

Gras

Spain
|
2023-2023
  • Adults
  • Elderly
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Colaneri

Italy
|
2021-2023
  • Adults
  • Elderly
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Drysdale

Belgium
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Paediatric
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab

COCOPREV

France
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Rinaldi

Italy
|
2022-2022
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Rotundo

Italy
|
2022-2023
  • Adults
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Colaneri

Italy
|
2021-2022
  • Adults
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir